Send to

Choose Destination
J Reprod Immunol. 2009 Jul;81(1):34-8. doi: 10.1016/j.jri.2009.04.002. Epub 2009 Jun 6.

CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa.

Author information

Institute of Health and Biomedical Innovation, Queensland University of Technology, 60 Musk Ave, Brisbane QLD 4059, Australia.


Chlamydia trachomatis is a significant human pathogen with potentially severe disease sequelae in the genital tract, including infertility. A successful vaccine will need to effectively target immunity to the genital mucosa. Intranasal immunisation with cholera toxin (CT) can target immunity to the genital tract, but has the potential to cause neurological side effects. CTA1-DD is a non-toxic potent mucosal adjuvant which combines the enzymatic properties of CT, with a B cell targeting moiety. Here, we demonstrate that intranasal immunisation with CTA1-DD and chlamydial Major Outer Membrane Protein (MOMP) results in the induction of neutralising systemic and mucosal antibodies, and reduces the level of chlamydial shedding following intravaginal challenge with Chlamydia muridarum. Thus, CTA1-DD is an effective adjuvant for vaccine development against Chlamydia trachomatis, and possibly also a range of other genital pathogens.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center